Cancer Stem Cell Markers for Urinary Carcinoma

Pu, Xia; Liu, Da-Hua; Xu, Ze-Jun; Ren, Fu

doi:10.1155/2022/3611677

Cited by 10 publications

(8 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 15 16 ] There is high expression of CXCR4 on cancer stem cells that are mainly responsible for tumor resistance to anticancer therapies and relapse. [ 17 18 19 ] Targeting cancer stem cells through CXCR4 receptors is a promising approach to combat various malignancies effectively. Although many studies reporting various targeted delivery systems exist,[ 20 ] only a few revolve around CXCR4 receptor targeting.…”

Section: Discussionmentioning

confidence: 99%

Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide

Ansari,

Mudassir,

Vijayalekshmi

et al. 2023

International Journal of Applied &Amp; Basic Medical Research

View full text Add to dashboard Cite

Background: Chemokine receptor CXCR4 is frequently present in cells of various cancers. Hence, targeted therapy using CXCR4 ligands, such as DV1 peptide, on drug-loaded nanoparticles, has the potential to enhance the efficiency of cancer treatment. Aim: The present study created a CXCR4-targeting drug delivery system using avidin-poly (lactic-co-glycolic acid) (PLGA) nanoparticle surface tagged with biotinylated DV1 peptide ligand. Materials and Methods: A double-emulsion solvent evaporation technique was employed to prepare avidin-PLGA nanoparticles and characterized by transmission electron microscopy (TEM) and dynamic light scattering. Uptake was studied by confocal microscopy after incorporating fluorescein isothiocyanate (FITC)-labeled albumin inside the nanoparticles during their synthesis. Peptide-biotin-avidin-PLGA nanoparticles were tested in vitro on CXCR4-expressing U87MG cells. Photomicroscopy was done by a Nikon A1 Confocal Microscope, and pictures were analyzed by Nikon NIS-Elements BR software. Results: Experimental results confirmed the specificity of DV1 peptide-tagged avidin-PLGA nanoparticles for cells expressing CXCR4 receptors. The avidin-PLGA nanoparticles were successfully synthesized and the same was confirmed by tagging them with FITC-labeled biotin. Conclusion: Avidin-PLGA nanoparticle surface tagged with biotinylated DV1 peptide ligand has potential clinical application in the treatment of various cancers as targeted therapy for CXCR4-expressing cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide

Ansari,

Mudassir,

Vijayalekshmi

et al. 2023

International Journal of Applied &Amp; Basic Medical Research

View full text Add to dashboard Cite

show abstract

“…CSCs have been proposed to play a major role in tumorigenesis, drug resistance, metastasis, and cancer relapse, because of their ability for self-renewal [ 48 ]. The subpopulation of CSCs that remains in tumor tissue following chemotherapy is responsible for survival and expansion of tumor cells during recurrence [ 49 , 50 ].…”

Section: Drug Resistance Regulation By Bladder Cancer (Bc) Stem Cellsmentioning

confidence: 99%

“…CSCs can be renitent to DNA damage-induced cell death through different ways. These ways include protection against oxidative DNA damage by enhanced ROS scavenging, promotion of the DNA repair capability through ATM and CHK1/CHK2 phosphorylation, or activation of the anti-apoptotic signaling pathways, such as PI3K/Akt, WNT/b-catenin, and Notch signaling pathways [ 47 , 50 ] ( Fig. 3 ).…”

Section: Drug Resistance Regulation By Bladder Cancer (Bc) Stem Cellsmentioning

confidence: 99%

Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics

Farouk,

Khafaga,

Abdellatif

2023

Cancer Cell Int

View full text Add to dashboard Cite

Bladder cancer (BC) is the sixth most common worldwide urologic malignancy associated with elevated morbidity and mortality rates if not well treated. The muscle-invasive form of BC develops in about 25% of patients. Moreover, according to estimates, 50% of patients with invasive BC experience fatal metastatic relapses. Currently, resistance to drug-based therapy is the major tumble to BC treatment. The three-dimensional (3D) cell cultures are clearly more relevant not only as a novel evolving gadget in drug screening but also as a bearable therapeutic for different diseases. In this review, various subtypes of BC and mechanisms of drug resistance to the commonly used anticancer therapies are discussed. We also summarize the key lineaments of the latest cell-based assays utilizing 3D cell culture systems and their impact on understanding the pathophysiology of BC. Such knowledge could ultimately help to address the most efficient BC treatment.

show abstract

“…Additional markers are also used for the identification of BSCSC namely MAGE-A3 (Melanoma antigen family A, 3)[ 88 ], BCMab1[ 79 ], and several members of the cytokeratin family of proteins (CK5 + , CK17 + , CK18 - , CK20 - )[ 89 ].…”

Section: Tissue-specific Cancer Stem Cellsmentioning

confidence: 99%

Tissue-specific cancer stem/progenitor cells: Therapeutic implications

Yehya,

Youssef,

Hachem

et al. 2023

World J Stem Cells

View full text Add to dashboard Cite

Surgical resection, chemotherapy, and radiation are the standard therapeutic modalities for treating cancer. These approaches are intended to target the more mature and rapidly dividing cancer cells. However, they spare the relatively quiescent and intrinsically resistant cancer stem cells (CSCs) subpopulation residing within the tumor tissue. Thus, a temporary eradication is achieved and the tumor bulk tends to revert supported by CSCs' resistant features. Based on their unique expression profile, the identification, isolation, and selective targeting of CSCs hold great promise for challenging treatment failure and reducing the risk of cancer recurrence. Yet, targeting CSCs is limited mainly by the irrelevance of the utilized cancer models. A new era of targeted and personalized anti-cancer therapies has been developed with cancer patient-derived organoids (PDOs) as a tool for establishing pre-clinical tumor models. Herein, we discuss the updated and presently available tissue-specific CSC markers in five highly occurring solid tumors. Additionally, we highlight the advantage and relevance of the three-dimensional PDOs culture model as a platform for modeling cancer, evaluating the efficacy of CSC-based therapeutics, and predicting drug response in cancer patients.

show abstract

Cancer Stem Cell Markers for Urinary Carcinoma

Cited by 10 publications

References 80 publications

Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide

Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with Biotinylated DV1 Peptide

Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics

Tissue-specific cancer stem/progenitor cells: Therapeutic implications

Contact Info

Product

Resources

About